MGC Pharma smashes major milestones


Specialist ASX pot-stock, MGC Phama (ASX:MXC), has released its quarterly activities for the period ending June 30 2018, reporting strong progress across all of its business divisions and clinching a string of major milestones. Particularly robust progress has been seen within the MGC Pharma division, with the final GMP certificate and manufacturing licence received for its Slovenian facility. Pivotally, this certification makes MXC’s facility one of the most advanced of its kind within Europe. This fully integrated facility also plays nicely into MXC’s ‘seed-to-pharma’ strategy. The facility is now fully licensed to produce and manufacture pharmaceutical-grade medicines containing both THC (tetrahydrocannabinol) and CBD (cannabidiol) active pharmaceutical ingredients (APIs). MXC has begun full-scale manufacturing of CannEpilTM—its first medicinal cannabis treatment for drug-resistant or refractory epilepsy — which will then undergo final independent validation by the National Institute of Chemistry in Slovenia ahead of planned exportation into Australasia and Europe. MGC Pharma smashes major milestones

thumbnail courtesy of


Please enter your comment!
Please enter your name here